Comparing venetoclax in combination with hypomethylating agents to hypomethylating agent-based therapies for treatment naive TP53-mutated acute myeloid leukemia: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)
Blood Cancer J. 2024 Feb 20;14(1):32.
doi: 10.1038/s41408-024-01000-2.
- PMID: 38378617
- PMCID: PMC10879201
- DOI: 10.1038/s41408-024-01000-2
Abstract
Publication types
- Comparative Study
- Letter
- Research Support, Non-U.S. Gov't
- Research Support, N.I.H., Extramural
MeSH terms
- Antineoplastic Combined Chemotherapy Protocols / pharmacology
- Antineoplastic Combined Chemotherapy Protocols / therapeutic use
- Bridged Bicyclo Compounds, Heterocyclic / pharmacology
- Bridged Bicyclo Compounds, Heterocyclic / therapeutic use
- Humans
- Leukemia, Myeloid, Acute* / drug therapy
- Leukemia, Myeloid, Acute* / genetics
- Leukemia, Myeloid, Acute* / pathology
- Sulfonamides / pharmacology
- Sulfonamides / therapeutic use
- Tumor Suppressor Protein p53 / genetics
Substances
- Bridged Bicyclo Compounds, Heterocyclic
- Sulfonamides
- TP53 protein, human
- Tumor Suppressor Protein p53
- venetoclax